Prostate Cancer Therapy
Antibody-chemotherapeutic conjugate designed for prostate cancer therapy
Published in Cancer Weekly, January 11th, 2005
According to recent research from the United States, "MLN2704 is an antibody-chemotherapeutic conjugate designed to target prostate-specific membrane antigen (PSMA). PSMA is a transmembrane receptor whose expression is largely restricted to prostatic epithelium and prostate cancer cells with its expression level increasing during the progression of malignancy. MLN2704 consists of a de-immunized, monoclonal antibody that is specific for PSMA conjugated to drug may-tansinoid 1 (DM1), a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-01-11)
More Articles from Cancer Weekly
- Breast Cancer
Novel enzyme protects breast tumor cells from oxidative stress - Breast Cancer
Study finds radiation therapy may not be needed after breast cancer surgery - Cancer Genetics
PIK3CA is an oncogene in ovarian cancer, common mutation in early breast cancer - Cancer Immunology
Human body makes antibodies that recognize metastatic breast cancer tumors - Acute Leukemia Therapy
FLAD regimen shows promise for high-risk patients - Acute Myelogenous Leukemia
Farnesyl transferase inhibitor can help patients at high-risk for AML - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
